AXON’s AADvac1 Tau Vaccine One of the Hot Topics at CTAD 2015 Conference

BARCELONA, Spain–(BUSINESS WIRE)–AXON Neuroscience presented encouraging Phase 1 study results of the company’s active tau vaccine AADvac1 at the opening session of the 8th International Conference on Clinical Trials in Alzheimer’s Disease (CTAD). At the session, called Hot Topics in AD Clinical Trials, AXON demonstrated an excellent safety and immunogenicity profile of the AADvac1 from the finished Phase 1 study. AXON’s second presentation at CTAD presented the exceptional preclinical results of the passive vaccine AADvac2, another lead compound of the company. AADVAC1 TAU ACTIVE THERAPY AXON’s vaccine AADvac1 stimulates patients’ immune systems to generate specific antibodies against diseased forms of tau protein and thus protect the brain from neurodegeneration. The vaccine is intended to be a disease-modifying drug for Alzheimer’s disease. At the CTAD 2015 presentation, AXON’s Medical Director, Matej…


Link to Full Article: AXON’s AADvac1 Tau Vaccine One of the Hot Topics at CTAD 2015 Conference